Full-Time
Manufactures robotic surgical systems and services
No salary listed
Sunnyvale, CA, USA
Hybrid
See people who can refer or advise you
Intuitive Surgical designs, manufactures, and sells robotic surgical systems and provides related services and accessories for minimally invasive surgery. The core product helps surgeons perform operations with enhanced precision by guiding robotic arms controlled from a console, allowing procedures to be done through small incisions. Instruments and consumables are used with the systems and are supported by service contracts, creating a recurring revenue stream. Compared to competitors, Intuitive has a large installed base and focuses specifically on robotic-assisted surgery, combining devices, disposable instruments, and ongoing services to support hospitals and surgical centers. Its goal is to improve patient outcomes by enabling safer, less invasive procedures while expanding the use and capabilities of robotic surgery for more procedures and providers.
Company Size
10,001+
Company Stage
IPO
Headquarters
Sunnyvale, California
Founded
1995
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Hybrid Work Options
Medtronic and Intuitive Surgical, two medical device leaders, have underperformed this year due to sector weakness and company-specific challenges. However, both show potential for recovery. Medtronic's fourth-quarter revenue rose 9.9% to $9.8 billion, though adjusted earnings per share fell 4.3% to $1.55 due to higher costs, including tariffs. The company posted its highest annual revenue growth in a decade, driven partly by its Pulse Field Ablation franchise. Medtronic recently received FDA clearance for its Hugo robotic-assisted surgery system for urologic procedures, positioning it to compete in the underpenetrated robotic surgery market. The company plans to spin off its lower-margin diabetes care division, which should improve margins. With a 3.4% forward dividend yield and 49 consecutive years of payout increases, Medtronic appeals to income-focused investors.
Intuitive Surgical's stock has fallen 27% over the past twelve months, now trading 41% below its two-year high. The robotic surgery pioneer trades at 40.8 times earnings, the highest valuation in its sector. The company maintains a 31% operating margin, outpacing Johnson & Johnson's 27% and Medtronic's 18.8%. Revenue grew 21% over the last twelve months. The firm placed 468 da Vinci systems in the most recent quarter, an 18% increase year-over-year, driven by demand for its new da Vinci 5 platform. However, US procedure growth slowed to 12%, compared to 15% worldwide growth. Management attributed the slowdown to changes in patient coverage and premium dynamics causing treatment deferrals.
Intuitive Surgical reported second-quarter revenue of $2.89 billion, up 19% year-on-year and beating Wall Street estimates. Despite this, shares fell 14.1% to a new 52-week low on Friday. The drop followed concerns about slowing US procedure volumes. Whilst global procedures grew 16%, growth for da Vinci systems in the critical US market moderated to 12%. Management noted that changes in patient coverage may be affecting demand for elective procedures. Paradoxically, capital equipment sales remained strong, with 468 da Vinci systems placed in the quarter, up 18% year-on-year. US placements jumped 24%, driven by the new da Vinci 5 platform. Management also detailed plans for an extended use programme launching in 2027, aimed at reducing costs but potentially impacting high-margin recurring revenue.
Intuitive Surgical reported strong Q2 results, with revenue up 19% year-over-year to $2.89 billion and non-GAAP earnings per share rising 28% to $2.80. Recurring revenue accounted for 85% of total sales. Total procedures increased 16%, driven by 15% growth in da Vinci procedures and 36% growth in Ion procedures. Whilst US growth slowed, international da Vinci procedures rose 20%, expanding across Europe and Asia. The company maintained its 2026 procedure outlook, keeping da Vinci procedure growth guidance at 13.5% to 15.5% whilst raising its non-GAAP gross margin forecast to 68% to 69%. Management highlighted continued demand for newer platforms including da Vinci 5, SP and Ion. The installed base grew to nearly 13,000 systems worldwide.
Intuitive Surgical reported second-quarter revenue of $2.89 billion, up 18.5% year on year and beating Wall Street estimates of $2.82 billion. The medical technology company's non-GAAP profit of $2.80 per share exceeded analyst expectations by 11.9%. Despite the strong results, the stock declined. The drop was attributed to recent declines in overall surgery volumes reported by major healthcare providers and a Class II recall of certain da Vinci surgical components. Operating margin improved to 33.6%, up from 30.5% in the same quarter last year. Analysts expect revenue to grow 12.5% over the next 12 months, representing a deceleration from recent growth rates. The company has demonstrated solid long-term performance, with 16.4% annualised revenue growth over the past five years.